All In Biotech

Drug Trial Radar · NCT07905352

A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-Blind, placebo-controlled Phase 2 clinical study to evaluate the efficacy and safety of Simenafil Hydrochloride Tablets in the treatment of participants with Alzheimer's Disease

Conditions

  • Alzheimer Disease

Interventions

  • Simenafil Hydrochloride Tablets 2.5 mgDrug

    Simenafil Hydrochloride Tablets 1 tablet (2.5mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (10mg/tablet)

  • Simenafil Hydrochloride Tablets 5 mgDrug

    Simenafil Hydrochloride Tablets 1 tablet (5mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (10mg/tablet)

  • Simenafil Hydrochloride Tablets 10 mgDrug

    Simenafil Hydrochloride Tablets 1 tablet (10mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (5mg/tablet)

  • Placebo TabletsDrug

    Simenafil Hydrochloride Tablets placebo 1 tablet (5mg/tablet) + Simenafil Hydrochloride Tablets placebo 1 tablet (10mg/tablet)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)Time frame: 52 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital ,Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.